0

Ergoloid Mesylates and ECT

G S Sachs, A J Gelenberg, B Bellinghausen, J Wojcik, W E Falk, A M Farhadi, M Jenike

J Clin Psychiatry. 1989 Mar;50(3):87-90.

PMID: 2647711

Abstract:

Amnesia is the most common adverse effect among patients receiving electroconvulsive therapy. In a double-blind pilot study, patients receiving bilateral ECT were pretreated with ergoloid mesylates (N = 5) or placebo (N = 5). Consistent with the hypothesis that ergoloid mesylates might protect against ECT-associated amnesia, nonsignificant trends on some memory tests showed better performance for patients receiving active treatment. Unexpectedly, patients treated with ergoloid mesylates had a significantly better antidepressant response.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP8067241 Ergoloid mesylates Ergoloid mesylates 8067-24-1 Price
qrcode